Physician profile
Mitchell E Simons
NPI 1215003355
$5,449.38
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,798 · 2020: $1,861 · 2021: $765 · 2024: $24.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $874.58 | 2019-2021 | |
| Pfizer INC. | $684.78 | 2019-2021 | |
| Amgen INC. | $673.76 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $478.77 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $433.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $414.87 | 2019-2021 | |
| Assertio Therapeutics, INC. | $319.39 | 2019-2020 | |
| Daiichi Sankyo INC. | $310.76 | 2019 | |
| Biodelivery Sciences International, INC. | $272.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $146.26 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.76 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $64.70 | 2019-2021 | |
| Zyla Life Sciences, INC. | $61.58 | 2019-2020 | |
| Lilly USA, LLC | $57.36 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $56.32 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $48.47 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $39.86 | 2019 | |
| Nevro Corp. | $38.64 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $36.01 | 2019-2020 | |
| Eisai INC. | $30.16 | 2021 | |
| Allergan, INC. | $29.68 | 2020 | |
| Supernus Pharmaceuticals, INC. | $27.23 | 2019 | |
| Scilex Pharmaceuticals INC. | $27.22 | 2020 | |
| Tersera Therapeutics LLC | $25.18 | 2019 | |
| Abiomed | $24.60 | 2024 | Impella |
| Horizon Therapeutics Plc | $23.65 | 2020-2021 | |
| Kaleo, INC. | $23.12 | 2019 | |
| Grt US Holding, INC. | $19.03 | 2021 | |
| Si-Bone, INC. | $18.63 | 2019 | |
| Almatica Pharma LLC | $16.79 | 2021 | |
| Bioventus LLC | $13.10 | 2021 | |
| Redhill Biopharma INC. | $12.94 | 2020 | |
| Medline Industries Lp | $12.91 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.